pp-172 Concentrate for solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Non-small cell lung cancer (NSCLC); oesophageal squamous cell carcinoma (ESCC)
Clinical stage: Phase 2 — ongoing in NSCLC and ESCC
Modality: Biologic (antibody-drug conjugate; anti-PD-L1 mAb conjugated to cytotoxin)
Mechanism / Target: PD-L1-targeted ADC — delivers cytotoxic payload to PD-L1-expressing tumour cells and immunosuppressive cells in TME; dual mechanism: direct cytotoxicity + checkpoint relief via PD-L1 blockade
Route / form: Intravenous infusion
Differentiation: First PD-L1-targeting ADC in clinical development; combines checkpoint inhibition with targeted cytotoxicity; targets high PD-L1 tumour burden in NSCLC and ESCC
Manufacturer #15340
Clinical-stage and commercial biopharmaceutical company specialising in oncology biologics. Combines proprietary monoclonal antibody and ADC technologies for gastrointestinal and lung cancers. Wholly owned pipeline with Phase 3 and Phase 2 assets advancing globally.
None